51
|
Politikos I, Devlin SM, Mazis C, Maloy MA, Naputo K, Afuye A, Avecilla ST, Castro-Malaspina H, Dahi PB, Giralt SA, Sauter CS, Scordo M, Shaffer BC, Shah GL, Tamari R, Perales MA, Scaradavou A, O'Reilly RJ, Cho C, Gyurkocza B, Hsu KC, Jakubowski AA, Papadopoulos EB, van den Brink MR, Young JW, Ponce DM, Barker JN. Double-Unit Cord Blood (CB) Transplantation (dCBT) Supplemented with Haplo-Identical CD34+ Cells May be Associated with Enhanced Neutrophil Recovery but Successful Myeloid Bridging Is Strongly Influenced By Haplo CD34+ Cell Dose and Haplo-Winning CB Unit HLA-Match. Biol Blood Marrow Transplant 2019. [DOI: 10.1016/j.bbmt.2018.12.284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
52
|
Fonseca M, Jakubowski AA, Devlin SM, Young JW, Fatmi S, Maloy MA, Giralt SA, Ponce DM, Markova A. HLA-a*0101 Allele Is Associated with Increased Risk of Cutaneous Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2019. [DOI: 10.1016/j.bbmt.2018.12.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
53
|
Markey KA, Gomes A, Littmann E, Devlin SM, Slingerland AE, Moore G, Fatmi S, Slingerland J, Clurman A, Maloy MA, Pamer EG, Taur Y, Giralt SA, Perales MA, Ponce DM, Peled JU, van den Brink MR. Pre-Transplant and Peri-d100 Gastrointestinal Dysbiosis Is Associated with the Subsequent Development of Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2019. [DOI: 10.1016/j.bbmt.2018.12.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
54
|
Reshef R, Saber W, Bolaños-Meade J, Chen GL, Chen YB, Ho VT, Ponce DM, Nakamura R, Martens MJ, Hansen JA, Levine JE. Acute Gvhd Diagnosis and Adjudication in a Multicenter Trial – a Report from the BMT CTN 1202 Biorepository Study. Biol Blood Marrow Transplant 2019. [DOI: 10.1016/j.bbmt.2018.12.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
55
|
Politikos I, Cho C, Devlin SM, Maloy MA, Naputo K, O'Reilly RJ, Scaradavou A, Castro-Malaspina H, Dahi PB, Gyurkocza B, Jakubowski AA, Papadopoulos EB, Ponce DM, Sauter CS, Scordo M, Shaffer BC, Shah GL, Tamari R, van den Brink MR, Young JW, Giralt SA, Perales MA, Barker JN. Comparison of Double Unit Cord Blood Transplants (dCBT) with 8/8 HLA-Allele Matched Related (MRD) or Unrelated Donor (MUD) T-Cell Depleted (TCD) Transplants in Adults with Myeloid Malignancies: Comparable Progression-Free Survival (PFS). Biol Blood Marrow Transplant 2019. [DOI: 10.1016/j.bbmt.2018.12.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
56
|
Dierov D, Ciolino C, Fatmi S, Prockop SE, Perales MA, Ponce DM. Establishing a Standardized System to Capture Chronic GRAFT-Versus-Host Disease (GVHD) DATA in Accordance to the National Institutes of Health (NIH) Consensus Criteria. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
57
|
Preston EV, Chinapen S, Borrill T, Davis E, Shaffer BC, Tamari R, Jakubowski AA, Perales MA, Ponce DM, Shah GL, Dahi PB, Barker JN, Berman E, Tallman M, Giralt SA, Stein E, Gyurkocza B. Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
58
|
Bhatt V, Politikos I, Devlin SM, Jacob AG, Maloy M, Naputo K, Afuye A, Scaradavou A, O'Reilly RJ, Castro-Malaspina H, Dahi PB, Giralt SA, Gyurkocza B, Jakubowski AA, Papadopoulos EB, Peled JU, Hanash AM, Perales MA, Sauter CS, Shaffer BC, Shah GL, Tamari R, van den Brink MR, Young JW, Ponce DM, Barker JN. Therapeutic Cyclosporine-a (CSA) Levels in the First 7 Days after Cord Blood Transplantation (CBT) Are Critical to Prevent Severe Acute Graft-Versus-Host Disease (aGVHD). Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
59
|
Markova A, Pulitzer M, Jain M, Dierov D, Dahi PB, Gyurkocza B, Sauter CS, Spitzer B, Barker JN, Ponce DM. De Novo Skin Xerosis in Cord Blood Transplantation is Associated with Distinct Histopathology and Treatment Response: First Literature Report of Cord Dermatosis. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.305] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
60
|
Lau C, Politikos I, Devlin SM, Jacob AG, Maloy M, Naputo K, Afuye A, Bhatt V, Dahi PB, Perales MA, Giralt SA, O'Reilly RJ, Ponce DM, Prockop SE, Shah GL, Papanicolaou GA, Scaradavou A, Barker JN. Analysis of Cytomegalovirus (CMV) Infections in the First 180 Days in Adult Sero-Positive Cord Blood Transplantation (CBT) Recipients Reveals High Infection Rates and Treatment Burden. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
61
|
Abdel-Wahab O, Abrahm JL, Adams S, Adewoye AH, Allen C, Ambinder RF, Anasetti C, Anastasi J, Anderson JA, Antin JH, Antony AC, Araten DJ, Armand P, Armstrong G, Armstrong SA, Arnold DM, Artz AS, Awan FT, Baglin TP, Benson DM, Benz EJ, Berliner N, Bhagat G, Bhardwaj N, Bhatia R, Bhatia S, Bhatt MD, Bhatt VR, Bitan M, Blinderman CD, Bollard CM, Braun BS, Brenner MK, Brittenham GM, Brodsky RA, Brown M, Broxmeyer HE, Brummel-Ziedins K, Brunner AM, Buadi FK, Burkhardt B, Burns M, Byrd JC, Caimi PF, Caligiuri MA, Canavan M, Cantor AB, Carcao M, Carroll MC, Carty SA, Castillo JJ, Chan AK, Chapin J, Chiu A, Chute JP, Clark DB, Coates TD, Cogle CR, Connell NT, Cooke E, Cooley S, Corradini P, Creager MA, Creger RJ, Cromwell C, Crowther MA, Cushing MM, Cutler C, Dang CV, Danial NN, Dave SS, DeCaprio JA, Dinauer MC, Dinner S, Diz-Küçükkaya R, Dodd RY, Donato ML, Dorshkind K, Dotti G, Dror Y, Dunleavy K, Dvorak CC, Ebert BL, Eck MJ, Eikelboom JW, Epperla N, Ershler WB, Evans WE, Faderl S, Ferrara JL, Filipovich AH, Fischer M, Fredenburgh JC, Friedman KD, Fuchs E, Fuller SJ, Gailani D, Galipeau J, Gallagher PG, Ganapathi KA, Gardner LB, Gee AP, Gerson SL, Gertz MA, Giardina PJ, Gibson CJ, Golan K, Golub TR, Gonzales MJ, Gotlib J, Gottschalk S, Grant MA, Graubert TA, Gregg XT, Gribben JG, Gross DM, Gruber TA, Guitart J, Gurbuxani S, Gur-Cohen S, Gutierrez A, Hamadani M, Hari PN, Hartwig JH, Hayman SR, Hayward CP, Hebbel RP, Heslop HE, Hillis C, Hillyer CD, Ho K, Hockenbery DM, Hoffman R, Hogg KE, Holtan SG, Horny HP, Hsu YMS, Hunter ZR, Huntington JA, Iancu-Rubin C, Iqbal A, Isenman DE, Israels SJ, Italiano JE, Jaffe ES, Jaffer IH, Jagannath S, Jäger U, Jain N, James P, Jeha S, Jordan MB, Josephson CD, Jung M, Kager L, Kambayashi T, Kanakry JA, Kantarjian HM, Kaplan J, Karafin MS, Karsan A, Kaufman RJ, Kaufman RM, Keller FG, Kelly KM, Kessler CM, Key NS, Keyzner A, Khandoga AG, Khanna-Gupta A, Khatib-Massalha E, Klein HG, Knoechel B, Kollet O, Konkle BA, Kontoyiannis DP, Koreth J, Koretzky GA, Kotecha D, Kremyanskaya M, Kumari A, Kuzel TM, Küppers R, Lacy MQ, Ladas E, Landier W, Lapid K, Lapidot T, Larson PJ, Levi M, Lewis RE, Liebman HA, Lillicrap D, Lim W, Lin JC, Lindblad R, Lip GY, Little JA, Lohr JG, López JA, Luscinskas FW, Maciejewski JP, Majhail NS, Manches O, Mandle RJ, Mann KG, Manno CS, Marcogliese AN, Mariani G, Marincola FM, Mascarenhas J, Massberg S, McEver RP, McGrath E, McKinney MS, Mehta RS, Mentzer WC, Merlini G, Merryman R, Michel M, Migliaccio AR, Miller JS, Mims MP, Mondoro TH, Moorehead P, Muniz LR, Munshi NC, Najfeld V, Nayak L, Nazy I, Neff AT, Ness PM, Notarangelo LD, O'Brien SH, O'Connor OA, O'Donnell M, Olson A, Orkin SH, Pai M, Pai SY, Paidas M, Panch SR, Pande RL, Papayannopoulou T, Parikh R, Petersdorf EW, Peterson SE, Pittaluga S, Ponce DM, Popolo L, Prchal JT, Pui CH, Puigserver P, Rak J, Ramos CA, Rand JH, Rand ML, Rao DS, Ravandi F, Rawlings DJ, Reddy P, Reding MT, Reiter A, Rice L, Riese MJ, Ritchey AK, Roberts DJ, Roman E, Rooney CM, Rosen ST, Rosenthal DS, Rossmann MP, Rot A, Rowley SD, Rubnitz JE, Rydz N, Salama ME, Sauk S, Saunthararajah Y, Savage W, Scadden D, Schaefer KG, Schiffman F, Schneidewend R, Schrier SL, Schuchman EH, Scullion BF, Selvaggi KJ, Senoo K, Shaheen M, Shaz BH, Shelburne SA, Shpall EJ, Shurin SB, Siegal D, Silberstein LE, Silberstein L, Silverstein RL, Sloan SR, Smith FO, Smith JW, Smith K, Steensma DP, Steinberg MH, Stock W, Storry JR, Stramer SL, Strauss RG, Stroncek DF, Taylor J, Thota S, Treon SP, Tulpule A, Valdes RF, Valent P, Vedantham S, Vercellotti GM, Verneris MR, Vichinsky EP, von Andrian UH, Vose JM, Wagner AJ, Wang E, Wang JH, Warkentin TE, Wasserstein MP, Webster A, Weisdorf DJ, Weitz JI, Westhoff CM, Wheeler AP, Widick P, Wiley JS, William BM, Williams DA, Wilson WH, Wolfe J, Wolgast LR, Wood D, Wu J, Yahalom J, Yee DL, Younes A, Young NS, Zeller MP. Contributors. Hematology 2018. [DOI: 10.1016/b978-0-323-35762-3.00168-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
62
|
Mehta RS, Olson A, Ponce DM, Shpall EJ. Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. Hematology 2018. [DOI: 10.1016/b978-0-323-35762-3.00107-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
63
|
Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB, Ahr KF, Porosnicu Rodriguez KA, Shono Y, Slingerland AE, Docampo MD, Sung AD, Weber D, Alousi AM, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Taur Y, Pamer EG, Jenq RR, van den Brink MRM. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol 2017; 35:1650-1659. [PMID: 28296584 DOI: 10.1200/jco.2016.70.3348] [Citation(s) in RCA: 212] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relapse, graft-versus-host disease (GVHD), and infection. We have reported previously that alterations in the intestinal flora are associated with GVHD, bacteremia, and reduced overall survival after allo-HCT. Because intestinal bacteria are potent modulators of systemic immune responses, including antitumor effects, we hypothesized that components of the intestinal flora could be associated with relapse after allo-HCT. Methods The intestinal microbiota of 541 patients admitted for allo-HCT was profiled by means of 16S ribosomal sequencing of prospectively collected stool samples. We examined the relationship between abundance of microbiota species or groups of related species and relapse/progression of disease during 2 years of follow-up time after allo-HCT by using cause-specific proportional hazards in a retrospective discovery-validation cohort study. Results Higher abundance of a bacterial group composed mostly of Eubacterium limosum in the validation set was associated with a decreased risk of relapse/progression of disease (hazard ratio [HR], 0.82 per 10-fold increase in abundance; 95% CI, 0.71 to 0.95; P = .009). When the patients were categorized according to presence or absence of this bacterial group, presence also was associated with less relapse/progression of disease (HR, 0.52; 95% CI, 0.31 to 0.87; P = .01). The 2-year cumulative incidences of relapse/progression among patients with and without this group of bacteria were 19.8% and 33.8%, respectively. These associations remained significant in multivariable models and were strongest among recipients of T-cell-replete allografts. Conclusion We found associations between the abundance of a group of bacteria in the intestinal flora and relapse/progression of disease after allo-HCT. These might serve as potential biomarkers or therapeutic targets to prevent relapse and improve survival after allo-HCT.
Collapse
|
64
|
Sola M, Devlin SM, Maloy M, Dierov D, Barker JN, Castro-Malaspina H, Dahi P, Jakubowski AA, Koehne G, Papadopoulos EB, Sauter CS, Tamari R, van den Brink MR, Young JW, Giralt SA, Perales MA, Ponce DM. Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark Analysis. Biol Blood Marrow Transplant 2017. [DOI: 10.1016/j.bbmt.2016.12.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
65
|
Boughan KM, Dahi P, Devlin SM, Byam C, Yoo Y, Mazis C, Davis E, Nhaissi M, Paulson J, Wells DS, Cooper C, Ponce DM, Giralt SA, Papadopoulos EB, Kernan NA, Scaradavou A, Barker JN. Despite Increasing Size of Unrelated Donor (URD) Registries and the Global CB Inventory Racial Disparities in Access to URD and CB Grafts Persist: A Prospective 10 Year Analysis of 1,112 Patients. Biol Blood Marrow Transplant 2017. [DOI: 10.1016/j.bbmt.2016.12.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
66
|
Lau C, Bhatt V, Dahi P, Devlin SM, Yoo Y, Adel NG, Mazis C, Perales MA, Giralt SA, Koehne G, Ponce DM, Papanicolaou GA, Barker JN. Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients. Biol Blood Marrow Transplant 2017. [DOI: 10.1016/j.bbmt.2016.12.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
67
|
Politikos I, Devlin SM, Mazis C, Maloy M, Scaradavou A, Dahi P, Perales MA, Giralt SA, Ponce DM, Barker JN. A Novel Intermediate Intensity Conditioning Regimen Achieves High Rates of Long-Term Outpatient Progression-Free Survival Offsetting the Disadvantage of Early Post-Transplant Complications in Adult Cord Blood (CB) Transplant Recipients. Biol Blood Marrow Transplant 2017. [DOI: 10.1016/j.bbmt.2016.12.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
68
|
Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MRM, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM. Ex Vivo CD34 +-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Biol Blood Marrow Transplant 2016; 23:452-458. [PMID: 28017734 DOI: 10.1016/j.bbmt.2016.12.633] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Accepted: 12/20/2016] [Indexed: 11/29/2022]
Abstract
Ex vivo CD34+-selected T cell depletion (TCD) has been developed as a strategy to reduce the incidence of graft-versus-host disease (GVHD) after allogeneic (allo) hematopoietic stem cell transplantation (HSCT). Clinical characteristics, treatment responses, and outcomes of patients developing acute (aGVHD) and chronic GVHD (cGVHD) after TCD allo-HSCT have not been well established. We evaluated 241 consecutive patients (median age, 57 years) with acute leukemia (n = 191, 79%) or myelodysplastic syndrome (MDS) (n = 50, 21%) undergoing CD34+-selected TCD allo-HSCT without post-HCST immunosuppression in a single institution. Cumulative incidences of grades II-IV and III-IV aGVHD at 180 days were 16% (95% confidence interval [CI], 12 to 21) and 5% (95% CI, 3 to 9), respectively. The skin was the most frequent organ involved, followed by the gastrointestinal tract. Patients were treated with topical corticosteroids, poorly absorbed corticosteroids (budesonide), and/or systemic corticosteroids. The overall day 28 treatment response was high at 82%. The cumulative incidence of any cGVHD at 3 years was 5% (95% CI, 3 to 9), with a median time of onset of 256 days (range, 95 to 1645). The 3-year transplant-related mortality, relapse, overall survival, and disease-free survival were 24% (95% CI, 18 to 30), 22% (95% CI, 17 to 27), 57% (95% CI, 50 to 64), and 54% (95% CI, 47 to 61), respectively. The 1-year and 3-year probabilities of cGVHD-free/relapse-free survival were 65% (95% CI, 59 to 71) and 52% (95% CI, 45 to 59), respectively. Our findings support the use of ex vivo CD34+-selected TCD allograft as a calcineurin inhibitor-free intervention for the prevention of GVHD in patients with acute leukemia and MDS.
Collapse
|
69
|
Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MRM, Young JW, O'Reilly RJ, Giralt SA, Perales MA. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016; 23:67-74. [PMID: 27789361 DOI: 10.1016/j.bbmt.2016.10.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 10/15/2016] [Indexed: 12/20/2022]
Abstract
To evaluate the association between the hematopoietic cell transplantation-comorbidity index (HCT-CI) and the recently developed age-adjusted HCT-CI (HCT-CI/age) and transplant outcomes in the setting of CD34-selected allogeneic HCT, we analyzed a homogeneous population of patients undergoing allogeneic HCT with CD34-selected grafts for acute myeloid leukemia and myelodysplastic syndrome (n = 346). Median HCT-CI and HCT-CI/age scores were 2 (percentile 25 to 75, 1 to 4) and 3 (percentile 25 to 75, 1 to 5), respectively. Higher HCT-CI and HCT-CI/age scores were associated with higher nonrelapse mortality (NRM) and lower overall survival (OS). The HCT-CI distinguished 2 risk groups (0 to 2 versus ≥3), whereas, with the HCT-CI/age, there was a progressive increase in NRM and decrease in OS with increasing scores in all 4 groups (0 versus 1 to 2 versus 3 to 4 versus ≥5). Higher scores in both models were associated with lower chronic graft-versus-host disease relapse-free survival but not with higher relapse. Both models showed a promising predictive accuracy for NRM (c- = .616 for HCT-CI and c- = .647 for HCT-CI/age). In conclusion, the HCT-CI and HCT-CI/age predict transplant outcomes in CD34-selected allo-HCT, including NRM, OS, and chronic graft-versus-host disease relapse-free survival and may be used to select appropriate patients for this approach.
Collapse
|
70
|
Kosuri S, Hilden P, Devlin SM, Yoo Y, Lauer E, Peled JU, Avecilla S, Castro-Malaspina H, Dahi P, Giralt SA, Gyurkocza B, Jakubowski AA, Meagher R, Papadopoulos E, Perales MA, Reich L, Sauter CS, Scaradavou A, Shaffer B, Tamari R, van den Brink MR, Young JW, Ponce DM, Barker JN. High Progression-Free Survival (PFS) in Adult Double Unit Cord Blood (dCB) Transplant Recipients with High Risk Disease after a Novel Intermediate Intensity Conditioning Regimen. Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.370] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
71
|
Barba P, Ratan R, Ceberio I, Hilden P, Maloy M, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos E, Ponce DM, Sauter CS, van den Brink MR, Young JW, Avecilla S, Meagher R, Devlin SM, O'Reilly RJ, Giralt SA, Perales MA. The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
72
|
Bhatt V, Lin A, Beyer K, Proli AJ, Yoo Y, Lauer E, Giralt SA, Ponce DM, Barker JN. Analysis of Cyclosporine-a (CSA) Levels Supports New Dosing Guidelines in Adult Double Unit Cord Blood Transplant (dCBT) Recipients to Optimize Immunosuppression Early Post-Transplant. Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.1086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
73
|
Kosuri S, Wolff T, Lauer E, Byam C, Yoo Y, Davis E, Paulson J, Sideroff M, Wells DS, Perales MA, Scaradavou A, Giralt SA, Ponce DM, Barker JN. Prospective Evaluation of Cord Blood (CB) and Haplo-Identical (Haplo) Donor Availability Reveals Compromised Donor Access for Both CB and Haplo Grafts in Minority Patients. Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
74
|
Bhatt V, Palazzo M, Kilroy K, Hilden P, Devlin SM, Maloy M, Barker JN, Castro-Malaspina H, Chung DJ, Dahi P, Hsu KC, Hanash AM, Jakubowski AA, Jenq R, Koehne G, Landau H, Papadopoulos E, Perales MA, Sauter CS, Tamari R, van den Brink MR, Young JW, Giralt SA, Ponce DM. Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative Adult Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
75
|
Bekele S, Patterson E, Kelly S, Featherstone C, Giralt SA, Perales MA, Robilotti E, Jenq R, Ponce DM. Stool PCR for Clostridium Difficile Toxin B Is Frequently Detected at the First Stool Assay in the Immediate Peri-Transplant Period in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|